Literature DB >> 23954084

Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results.

Matthias C Roethke1, Timur H Kuru, Ali Afshar-Oromieh, Heinz-Peter Schlemmer, Boris A Hadaschik, Michael Fenchel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23954084     DOI： 10.1016/j.eururo.2013.08.003

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  13 in total

1.  [MRI/PET for the detection of bone metastases. The new gold standard?].

Authors:  M-A Weber
Journal:  Radiologe       Date:  2015-09       Impact factor: 0.635

2.  Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.

Authors:  Ali Afshar-Oromieh; Maya Wolf; Uwe Haberkorn; Marc Kachelrieß; Regula Gnirs; Klaus Kopka; Heinz-Peter Schlemmer; Martin T Freitag
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-15       Impact factor: 9.236

Review 3.  [Imaging diagnostics in bone metastases].

Authors:  L Kintzelé; M-A Weber
Journal:  Radiologe       Date:  2017-02       Impact factor: 0.635

4.  [Interdisciplinary and individualized therapy of prostate cancer : International prostate cancer symposium Bonn 2013 - challenges and targets].

Authors:  M Schwardt; J Debus; G Feick; B Hadaschik; M Hohenfellner; R Schüle; J-P Zacharias; S E Combs
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

Review 5.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

6.  Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013".

Authors:  Stephanie E Combs; Jürgen Debus; Günter Feick; Boris Hadaschik; Markus Hohenfellner; Roland Schüle; Jens-Peter Zacharias; Malte Schwardt
Journal:  Radiat Oncol       Date:  2014-11-04       Impact factor: 3.481

7.  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

8.  Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?

Authors:  Thampi John Nirmal; Nitin S Kekre
Journal:  Indian J Urol       Date:  2015 Jan-Mar

Review 9.  (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors:  Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal:  Cancer Imaging       Date:  2016-06-08       Impact factor: 3.909

Review 10.  The current and future role of magnetic resonance imaging in prostate cancer detection and management.

Authors:  Jan Philipp Radtke; Dogu Teber; Markus Hohenfellner; Boris A Hadaschik
Journal:  Transl Androl Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.